Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Discovery Laboratories Inc (DSCO)

DSCO RSS Feed
Add DSCO Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator
Search This Board:
Last Post: 11/7/2014 1:04:42 PM - Followers: 101 - Board type: Free - Posts Today: 0

The Big Day is Coming!!!!!!!!!!


 The FDA classified the review of the Complete Response as a Class 2 review and established March 6, 2012 as the target action date under the Prescription Drug User Fee Act (PDUFA) to complete its review and potentially grant marketing approval for SURFAXIN.

 





Discovery Laboratories, Inc., a biotechnology company, engages in developing surfactant therapies to treat respiratory disorders and diseases based on its KL4 surfactant and capillary aerosol-generating technologies. Its development stage products include Surfaxin, a synthetic, peptide-containing surfactant in phase III clinical trial for the prevention of respiratory distress syndrome in premature infants; Surfaxin LS, a Phase III trial product to improve ease of use for healthcare practitioners; and Aerosurf, an aerosolized KL4 surfactant that has completed first pilot Phase II clinical trial for the treatment of respiratory distress syndrome in premature infants.

The company has a license agreement with Philip Morris USA Inc. to use its capillary aerosolization technology for use with pulmonary surfactants for the respiratory diseases and conditions; and a strategic alliance agreement with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products in Andorra, Greece, Italy, Portugal, and Spain.

Discovery Laboratories, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.



 

MUST READ!!!!!!!!!!!!!!!!!

  On May 11, 2011, the Company issued a press release highlighting the results of operations for the quarter ended March 31, 2011, and providing an update on its pipeline development as follows:
 
Surfaxin® (lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants: The Company is conducting a comprehensive preclinical program to validate its optimized biological activity test (BAT), a key remaining issue that must be addressed to potentially gain U.S. Food and Drug Administration (FDA) marketing approval for Surfaxin in the United States.  The Company has had several interactions with the FDA intended to ensure that the comprehensive preclinical program would ultimately satisfy the FDA.  In January 2011, the Company announced that the FDA had provided guidance to increase the sample size of a specific data set by testing additional Surfaxin batches.  To comply with the FDA's suggestion, the Company has successfully manufactured eight Surfaxin batches and presently plans to manufacture two additional Surfaxin batches for use in the comprehensive preclinical program. The Company presently plans to complete all related analytical testing and concordance studies, and be in a position to file a Surfaxin Complete Response in the third quarter of 2011.
 
Surfaxin LSTM (lyophilized lucinactant) for neonatal RDS :  The Company continues to advance this program. Its plans for 2011 include establishing a commercial-scale manufacturing capability at a cGMP-compliant contract manufacturer with expertise in lyophilized formulations and seeking regulatory guidance from the FDA and the European Medicines Agency (EMA) for the planned clinical development program.
 
Aerosolization Technology :  Recently, at the 2011 Pediatric Academic Societies Annual Meeting (PAS), new data was presented including: (i) a collaborative study indicating that aerosolized KL4 surfactant significantly improved lung function and survival when treating Acute Lung Injury in a well established preclinical model of this severe respiratory condition, (ii) a dose-ranging assessment of aerosolized KL4 surfactant in a widely recognized preclinical model of RDS, demonstrating significant improvement in lung function, lung structural integrity and pulmonary inflammatory mediator profile following treatment with aerosolized KL4 surfactant versus controls, and (iii) a study highlighting the Company's novel patient interface technology intended to increase the efficiency of pulmonary aerosol drug delivery to patients requiring positive pressure ventilatory support.
 
 
2

 

 
 
Regarding the Company's lead aerosolized KL4 surfactant program, Aerosurf® (aerosolized lucinactant for neonatal RDS), data from the preclinical dose ranging assessment study presented at PAS mentioned above suggests that, out of several doses tested, KL4 surfactant delivered via the Company's proprietary capillary aerosol generator during a 20 to 30 minute dosing interval results in the most favorable physiologic outcomes.  This study provides guidance for future clinical dosing strategies for this program. The Company's plans for 2011 include finalizing the clinical and potential commercial design of the capillary aerosol generator, finalizing the clinical and potential commercial design for the novel patient interface, and seeking regulatory guidance in the U.S. and Europe for the planned development program.
 
For the quarter ending June 30, 2011, the Company projects cash outflow of $5.8 million.

 





 

Investor Relations Contacts

John G. Cooper
Executive Vice President, Chief Financial Officer
Discovery Laboratories, Inc.
2600 Kelly Road, Suite 100
Warrington, PA 18976
Tel. 215.488.9490
Fax. 215.488.9391
jcooper@discoverylabs.com


 



As of November 8, 2011, 24,499,497 shares of the registrant's common stock, par value $0.001 per share, were outstanding

As of  May 2, 2011, 24,178,502 shares of the registrant's common stock, par value $0.001 per share, were outstanding.  AutAeeeeee

Authorized 50 Mill

85 BM's 5-15-11



 

 

 

2010-11 Press Releases

 

May 13, 2011 10-Q http://ih.advfn.com/p.php?pid=nmona&article=47677338 

May 13, 2011 http://ih.advfn.com/p.php?pid=nmona&article=47666790       A Brighter Decade Ahead for Biotech - Equity Research on Discovery Laboratories and Mylan Inc   

May 11, 2011 8k http://ih.advfn.com/p.php?pid=nmona&article=47626029     

May 19, 2010
Discovery Labs Achieves Key Milestone Towards Potential Surfaxin® Approval

May 17, 2010
Discovery Labs' KL4 Surfactant Demonstrates Potential Protective Role for Lung Transplantation in Established Preclinical Model

May 14, 2010
Discovery Labs' Phase 2a Aerosurf® Study Published in Journal of Aerosol Medicine and Pulmonary Drug Delivery

May 5, 2010
Surfaxin LSTM Improves Pulmonary Function and Reduces Lung Inflammation in Established Model of Respiratory Distress Syndrome

April 28, 2010
Discovery Labs' KL4 Surfactant Data to be Presented at Pediatric Academic Societies Annual Meeting and American Thoracic Society International Conference

April 27, 2010
Discovery Labs Provides Updates on Surfaxin®, Other Key Programs and First Quarter 2010 Financial Results

March 10, 2010
Discovery Labs Reports Fourth Quarter 2009 Financial Results and Provides Business Update

February 23, 2010
Discovery Labs Announces Completion of $16.5 Million Public Offering

February 18, 2010
Discovery Labs Prices $16.5 Million Public Offering of Common Stock and Warrants

February 17, 2010
Discovery Labs Announces Proposed Public Offering of Common Stock and Warrants

February 16, 2010
Discovery Labs Receives FDA Guidance Regarding Pathway to Potential SURFAXIN® Approval

January 19, 2010
POPG, a Key Component of Discovery Labs KL4 Surfactant, Identified as a Novel Anti-Viral Therapeutic Approach

 



Management Team View Bio

W. Thomas Amick, Interim CEO

Russell Clayton, D.O.
Vice President, Academic and Medical Affairs, Acting Head, Regulatory Affairs and Preclinical Research

Kathryn Cole
Senior Vice President, Human Resources

John G. Cooper
Executive Vice President, Chief Financial Officer

David L. Lopez, C.P.A., Esq.
Executive Vice President, General Counsel

Charles F. Katzer
Senior Vice President, Manufacturing Operations

Thomas F. Miller, Ph.D., MBA
Senior Vice President, Commercialization & Corporate Development

Gerald J. Orehostky
Senior Vice President, Quality Operations

Robert Segal, M.D., F.A.C.P.
Senior Vice President, Medical & Scientific Affairs, Chief Medical Officer

Mary B. Templeton, Esq.
Senior Vice President, Deputy General Counsel

 



Do your own DD & trade smart

(DSCO) Pre-Market Trading     (DSCO) After Hours Trading

(DSCO) Short

Technical Indicators (Barchart) 

Yahoo! Finance (i.e Real-Time)

Last update: June 03,2010

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
DSCO
Current Price
Volume:
Bid Ask Day's Range
Wiki
Option Chain for DSCO
DSCO News: Discovery Labs Partners with March of Dimes on 2015 Prematurity Awareness Campaign 11/19/2014 09:00:00 AM
DSCO News: Quarterly Report (10-q) 11/07/2014 05:23:24 PM
DSCO News: Initial Statement of Beneficial Ownership (3) 11/06/2014 01:36:15 PM
DSCO News: Current Report Filing (8-k) 11/06/2014 07:49:51 AM
DSCO News: Discovery Labs Reports Third Quarter 2014 Financial Results 11/06/2014 07:30:00 AM
PostSubject
#2429   Stock needs buyers, volume and more volume. SciGuy 03/25/12 12:22:26 AM
#2428   Roth Capital already covers DSCO and raised target king oil 03/24/12 10:35:16 AM
#2427   Howard Hughes is dead and cannot help your SciGuy 03/24/12 12:52:27 AM
#2426   One more time: An article is coming SciGuy 03/24/12 12:39:36 AM
#2425   Agreed 2.80 is the platform BUT what and Socaltrader22 03/23/12 03:28:59 PM
#2424   I don't know Jeremy Richards from Howard Hughes, nsomniyak 03/22/12 10:46:34 PM
#2423   Well, I could be a smart ass and SciGuy 03/22/12 08:22:38 PM
#2422   who's Jeremy Richards? king oil 03/22/12 07:39:33 PM
#2421   They'll be back in droves. Jeremy Richards SciGuy 03/22/12 07:00:35 PM
#2420   what happened to the buyers? Degreed 03/22/12 12:06:20 PM
#2419   ~ Friday! $DSCO ~ Earnings posted, pending or Penny Roger$ 03/22/12 01:27:46 AM
#2418   <<< $DSCO Links! >>> ~ MAC's Quick DD Penny Roger$ 03/22/12 01:27:37 AM
#2417   After Hours High Hit: 2.98 +.18 from todays deepman49 03/21/12 09:06:23 PM
#2416   After Hours: 2.88 +.08 (+2.86%) 7:59PM EDT deepman49 03/21/12 08:52:44 PM
#2415   Discovery Labs Announces Completion of $45.0 Million Public Offering deepman49 03/21/12 08:50:18 PM
#2414   Agreed but why would they? This will Socaltrader22 03/20/12 03:31:18 PM
#2413   Is the financing completed? I would like to BioChica 03/20/12 01:01:03 PM
#2412   Thank you deepman very good incite. And the Socaltrader22 03/20/12 10:46:29 AM
#2411   That is called STRONG ARM ROBBERY of investors AntiMarketMaker 03/19/12 10:48:32 PM
#2410   Cash Infusions Provide Needed Financial Strength For Discovery Laboratories deepman49 03/19/12 07:53:13 PM
#2409   i saw your 1.5-1.60 comment very often.. gave Smurfedtear 03/19/12 04:03:30 PM
#2408   Yea I said it was 20 percent of crazystockace 03/19/12 03:46:18 PM
#2407   YOU SAID THAT ABOUT THE PUBLIC OFFERING. Smurfedtear 03/19/12 03:30:13 PM
#2406   Get your DSCO shares here for 1.50 and crazystockace 03/19/12 10:13:42 AM
#2405   Its bottomed at these levels. It needs easymoney123 03/19/12 09:42:09 AM
#2404   Staying above $2.50 this week will be bullish imo. DAD2 03/19/12 06:58:25 AM
#2403   DSCO - Earnings expected Friday 03/23/2012 $tockfather 03/18/12 11:01:16 PM
#2402   Yes it does. "If earnings release is positive, deepman49 03/17/12 07:16:31 PM
#2401   DSCO will be cash rich until 2014. easymoney123 03/17/12 06:50:11 PM
#2400   1.75 for sure mark it $Green$ 03/17/12 04:09:29 PM
#2399   I think this drug is worth a lot. BioChica 03/17/12 08:54:09 AM
#2398   I can't remember a secondary offering that was crazystockace 03/17/12 12:49:32 AM
#2397   You better adjust your math bud. ddls 03/16/12 06:24:52 PM
#2396   Discovery expects net proceeds of $42.1 million from moronalert 03/16/12 06:01:06 PM
#2395   I hope Italian Sausage Laboratories Inc. sink under AntiMarketMaker 03/16/12 03:37:42 PM
#2394   I did not dump the 3.49s That AntiMarketMaker 03/16/12 02:47:47 PM
#2393   Someone needs to update the Ibox. It still $Green$ 03/16/12 01:49:27 PM
#2392   squeeze it for awhile so the muppets buy $Green$ 03/16/12 01:46:14 PM
#2391   I'm surprised no form 4's haven't been sighted already. ddls 03/16/12 01:40:42 PM
#2390   One of my posts from March 5th ddls 03/16/12 01:34:50 PM
#2389   Yeah....that kind of is dumb thinking on their part... DERBYBLOOD 03/16/12 01:33:01 PM
#2388   $45M in cash will go a long way king oil 03/16/12 01:25:15 PM
#2387   chop chop. chop it up, chop now. ddls 03/16/12 01:16:20 PM
#2386   See?? i told you it's not gonna fall Smurfedtear 03/16/12 01:01:02 PM
#2385   Found this on a message board on IV; manny t 03/16/12 12:12:53 PM
#2384   DSCO limbo lol $Green$ 03/16/12 10:23:06 AM
#2383   You have to be nuts here to buy crazystockace 03/16/12 10:15:39 AM
#2382   Im thinking they will move this up to $Green$ 03/16/12 09:52:55 AM
#2381   I'm beginning to think they should get Capetola back. sunspotter 03/16/12 09:47:23 AM
#2380   Would not go there yet, earnings are next DAD2 03/16/12 09:29:16 AM
PostSubject